High-Risk leukemia drug trial halted after blood clot concerns
NCT ID NCT01570868
Summary
This study tested whether the drug ponatinib could control an aggressive form of chronic myeloid leukemia when used as the first treatment. It involved 51 adults with newly diagnosed advanced leukemia. The trial was terminated early, and the drug carries a serious risk of causing potentially fatal blood clots in about 1 in 4 patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.